Article

Mycobacterium tuberculosis appears to lack α-ketoglutarate dehydrogenase and encodes pyruvate dehydrogenase in widely separated genes

Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA.
Molecular Microbiology (Impact Factor: 5.03). 09/2005; 57(3):859-68. DOI: 10.1111/j.1365-2958.2005.04741.x
Source: PubMed

ABSTRACT Mycobacterium tuberculosis (Mtb) persists for prolonged periods in macrophages, where it must adapt to metabolic limitations and oxidative/nitrosative stress. However, little is known about Mtb's intermediary metabolism or antioxidant defences. We recently identified a peroxynitrite reductase-peroxidase complex in Mtb that included products of the genes sucB and lpd, which are annotated to encode the dihydrolipoamide succinyltransferase (E2) and lipoamide dehydrogenase (E3) components of alpha-ketoglutarate dehydrogenase (KDH). However, we could detect no KDH activity in Mtb lysates, nor could we reconstitute KDH by combining the recombinant proteins SucA (annotated as the E1 component of KDH), SucB and Lpd. We therefore renamed the sucB product dihydrolipoamide acyltransferase (DlaT). Mtb lysates contained pyruvate dehydrogenase (PDH) activity, which was lost when the dlaT gene (formerly, sucB) was disrupted. Purification of PDH from Mtb yielded AceE, annotated as an E1 component of PDH, along with DlaT and Lpd. Moreover, anti-DlaT antibody coimmunoprecipitated AceE. Finally, recombinant AceE, DlaT and Lpd, although encoded by genes that are widely separated on the chromosome, reconstituted PDH in vitro with Km values typical of bacterial PDH complexes. In sum, Mtb appears to lack KDH. Instead, DlaT and Lpd join with AceE to constitute PDH.

Download full-text

Full-text

Available from: Hediye Erdjument-Bromage, Sep 17, 2014
0 Followers
 · 
90 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To understand the adaptation of Mycobacterium tuberculosis to the intracellular environment, we used comprehensive metabolite profiling to identify the biochemical pathways utilized during growth on cholesterol, a critical carbon source during chronic infection. Metabolic alterations observed during cholesterol catabolism centered on propionyl-CoA and pyruvate pools. Consequently, growth on this substrate required the transcriptional induction of the propionyl-CoA-assimilating methylcitrate cycle (MCC) enzymes, via the Rv1129c regulatory protein. We show that both Rv1129c and the MCC enzymes are required for intracellular growth in macrophages and that the growth defect of MCC mutants is largely attributable to the degradation of host-derived cholesterol. Together, these observations define a coordinated transcriptional and metabolic adaptation that is required for scavenging carbon during intracellular growth.
    Chemistry & biology 02/2012; 19(2):218-27. DOI:10.1016/j.chembiol.2011.12.016 · 6.59 Impact Factor
  • Source
    Understanding Tuberculosis - Deciphering the Secret Life of the Bacilli, 02/2012; , ISBN: 978-953-307-946-2
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tuberculosis is one of most pervasive, respiratory transmitted diseases and has spread to every corner of the globe. According World Health Organization report, as much as one-third of the world’s population is currently infected by tuberculosis. There has been considerable interest in the currently used antimycotubercular compounds to inhibit or prevent mycobacterium species. These mycobacterium species have developed resistant against currently used drugs and produced toxic effect on long duration of therapy. These agents have different structure and almost all compounds having heterocyclic ring having one and more than one heteroatoms. These observations have been guiding for the currently used and newly developed antitubercular agents that possess potent antimicrobial activity and their side effects, activity against multi drug resistance MDR, XDR mycobacterium, and also in patient co-infected with HIV/AIDS.
    Oriental Pharmacy and Experimental Medicine 03/2011; 12(1). DOI:10.1007/s13596-011-0020-8